New Guidelines for HER2-Negative Advanced Breast Cancer (FREE)

By Kelly Young Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The American Society of Clinical Oncology has …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news

Related Links:

Contributors : M Schmidt ; M GehrmannSeries Type : Expression profiling by arrayOrganism : Homo sapiensInterferons are crucial for adaptive immunity and play an important role in the immune landscape of breast cancer. Using microarray-based gene expression analysis, we examined the subtype specific prognostic significance of interferon- γ (IFN-γ) as a single gene as well as an IFN-γ signature covering the signaling pathway in 461 breast cancer patients. Prognostic significance of IFN-γ as well as the IFN-γ signature for metastasis-free survival (MFS) were examined using Kaplan Meier as well as...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
Patients with HR+, HER2- breast cancer at high risk of early recurrence on endothelial therapy could highly improve their invasive disease-free survival with adjuvant abemaciclib, a new trial shows.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Combining  abemaciclib with hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, interim analysis of a phase III study has suggested.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Condition:   Metastatic Breast Cancer Interventions:   Drug: Trastuzumab deruxtecan;   Drug: Durvalumab;   Drug: Paclitaxel;   Drug: Capivasertib;   Drug: Anastrozole;   Drug: Fulvestrant;   Drug: Capecitabine Sponsors:   AstraZeneca;   Daiichi Sankyo Company, Limited Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(European Society for Medical Oncology) Lugano, Switzerland, 20 September 2020 - Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Contributors : Denise Wolf ; Christina Yau ; Julia Wulfkuhle ; Emanuel F Petricoin III ; Laura van ‘t VeerSeries Type : Protein profiling by protein arrayOrganism : Homo sapiensThe AKT inhibitor MK2206 (M) was one of the experimental agents evaluated in I-SPY 2, a neoadjuvant platform trial for high risk, early stage breast cancer, and graduated in the HER2+, HR-, and HR-HER2+ signatures. Based on the hypotheses that since MK2206 is an enzymatic inhibitor of AKT, response to MK2206 may be predicted by the relative pre-treatment levels of phosphorylation of AKT kinase substrates, in pre-defined analyses we assessed 26...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Protein profiling by protein array Homo sapiens Source Type: research
Contributors : Denise Wolf ; Christina Yau ; Julia Wulfkuhle ; Emanuel F Petricoin III ; Laura van ‘t VeerSeries Type : Expression profiling by arrayOrganism : Homo sapiensThe AKT inhibitor MK2206 (M) was one of the experimental agents evaluated in I-SPY 2, a neoadjuvant platform trial for high risk, early stage breast cancer, and graduated in the HER2+, HR-, and HR-HER2+ signatures. Based on the hypotheses that since MK2206 is an enzymatic inhibitor of AKT, response to MK2206 may be predicted by the relative pre-treatment levels of AKT kinase substrates, in pre-defined analyses we assessed 10 genes in the HER-AKT-m...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
Publication date: Available online 19 September 2020Source: Biochimica et Biophysica Acta (BBA) - Gene Regulatory MechanismsAuthor(s): Yini Yang, Lavanya Choppavarapu, Kun Fang, Alireza S. Naeini, Bakhtiyor Nosirov, Jingwei Li, Ke Yang, Zhijing He, Yufan Zhou, Rachel Schiff, Rong Li, Yanfen Hu, Junbai Wang, Victor X. Jin
Source: Biochimica et Biophysica Acta (BBA) Gene Regulatory Mechanisms - Category: Genetics & Stem Cells Source Type: research
Condition:   Metastatic Breast Cancer Interventions:   Drug: Trastuzumab deruxtecan;   Drug: Durvalumab;   Drug: Paclitaxel;   Drug: Capivasertib;   Drug: Anastrozole;   Drug: Fulvestrant;   Drug: Capecitabine Sponsors:   AstraZeneca;   Daiichi Sankyo Company, Limited Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Tumor human epidermal growth factor receptor 2 (HER2) status is defined by either protein expression using immunohistochemistry (IHC) or gene amplification using fluorescence in situ hybridization (FISH). Approximately 20% of HER2-positive breast cancer is HER2 IHC 2+/FISH-positive. Unlike trastuzumab, it has not been studied whether the response to trastuzumab emtansine (T-DM1) differs according to HER2-positive status. We retrospectively identified and reviewed medical records of all patients with HER2-positive advanced breast cancer (ABC) who received T-DM1 in our hospital from October 2013 to December 2016. We compared...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Case Reports Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Primary Care